SNRPD2

Across TCGA pan-cancer cohorts, SNRPD2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of SNRPD2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SNRPD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNRPD2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, COAD, and BLCA are the cancer types where SNRPD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNRPD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+0.820	<.001	12	view →
COAD	Female	II,III,IV	+1.446	<.001	11	view →
BLCA	All	All	+0.583	<.001	11	view →
KIRP	All	III,IV	+0.900	<.001	10	view →
LIHC	Female	II,III,IV	+1.499	<.001	9	view →
HNSC	Male	IV	+0.938	<.001	8	view →
LUSC	Female	All	+1.048	<.001	6	view →
STAD	All	II,III,IV	+0.665	<.001	6	view →
LUAD	Female	All	+0.610	<.001	6	view →
BRCA	All	All	+0.323	<.001	6	view →
CHOL	Male	All	+2.466	<.001	5	view →
READ	All	II,III,IV	+0.922	.009	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

SNRPD2–KIRC

Open the KIRC breakdown →